NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.01. View Eiger Biopharmaceuticals' Earnings History.

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eiger Biopharmaceuticals.

5 brokerages have issued 1-year target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $10.72 to $35.00. On average, they anticipate Eiger Biopharmaceuticals' stock price to reach $24.68 in the next twelve months. This suggests a possible upside of 109.2% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

Media coverage about EIGR stock has trended negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the next few days. View News Stories for Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 416,500 shares, a decline of 12.4% from the January 15th total of 475,400 shares. Based on an average daily volume of 195,200 shares, the short-interest ratio is presently 2.1 days. Approximately 1.9% of the company's stock are sold short. View Eiger Biopharmaceuticals' Current Options Chain.

Some companies that are related to Eiger Biopharmaceuticals include Krystal Biotech (KRYS), Twist Bioscience (TWST), Adverum Biotechnologies (ADVM), BAVARIAN NORDIC/S (BVNRY), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Sangamo Therapeutics (SGMO), DBV TECHNOLOGIE/S (DBVT), Vericel (VCEL), Proteon Therapeutics (PRTO), Atara Biotherapeutics (ATRA), Cellectis (CLLS), Avrobio (AVRO) and Oyster Point Pharma (OYST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Concert Pharmaceuticals (CNCE), Exelixis (EXEL), Celldex Therapeutics (CLDX) and Catalyst Pharmaceuticals (CPRX).

Eiger Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (5.05%), Farallon Capital Management LLC (4.47%), EcoR1 Capital LLC (1.83%), State Street Corp (1.81%), P.A.W. Capital Corp (0.59%) and BVF Inc. IL (0.59%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

EIGR stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BVF Inc. IL, Broadfin Capital LLC, Renaissance Technologies LLC, P.A.W. Capital Corp, Credit Suisse AG, Farallon Capital Management LLC and KBC Group NV. View Insider Buying and Selling for Eiger Biopharmaceuticals.

EIGR stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, J. Goldman & Co LP, California Public Employees Retirement System, Sanders Morris Harris LLC, Tocqueville Asset Management L.P., Connor Clark & Lunn Investment Management Ltd., Bank of America Corp DE and State Street Corp. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EIGR stock can currently be purchased for approximately $11.80.

Eiger Biopharmaceuticals has a market capitalization of $289.04 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]